Aldeyra Therapeutics, Inc. (ALDX) Stock Rating Lowered by Zacks Investment Research

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “

A number of other analysts also recently issued reports on the company. ValuEngine downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Cowen and Company reissued an “outperform” rating and set a $14.00 price objective (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Canaccord Genuity reissued a “buy” rating and set a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Finally, HC Wainwright set a $18.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $15.95.

Shares of Aldeyra Therapeutics (ALDX) traded down 0.65% during mid-day trading on Tuesday, hitting $7.70. 526,216 shares of the stock were exchanged. The company has a 50-day moving average price of $6.18 and a 200-day moving average price of $5.03. The stock’s market cap is $48.09 million. Aldeyra Therapeutics has a 12 month low of $3.80 and a 12 month high of $11.90.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Equities analysts expect that Aldeyra Therapeutics will post ($1.63) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/10/aldeyra-therapeutics-inc-aldx-stock-rating-lowered-by-zacks-investment-research.html.

In other news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the stock in a transaction that occurred on Tuesday, September 19th. The stock was bought at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 28.40% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC purchased a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $104,000. Renaissance Technologies LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at about $132,000. Hikari Power Ltd boosted its holdings in Aldeyra Therapeutics by 186.4% during the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after acquiring an additional 70,196 shares during the period. Sabby Management LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at about $898,000. Finally, Vanguard Group Inc. boosted its holdings in Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares during the period. Institutional investors own 40.06% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segme

According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “

A number of other analysts also recently issued reports on the company. ValuEngine downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Cowen and Company reissued an “outperform” rating and set a $14.00 price objective (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Canaccord Genuity reissued a “buy” rating and set a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Finally, HC Wainwright set a $18.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $15.95.

Shares of Aldeyra Therapeutics (ALDX) traded down 0.65% during mid-day trading on Tuesday, hitting $7.70. 526,216 shares of the stock were exchanged. The company has a 50-day moving average price of $6.18 and a 200-day moving average price of $5.03. The stock’s market cap is $48.09 million. Aldeyra Therapeutics has a 12 month low of $3.80 and a 12 month high of $11.90.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Equities analysts expect that Aldeyra Therapeutics will post ($1.63) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/10/aldeyra-therapeutics-inc-aldx-stock-rating-lowered-by-zacks-investment-research.html.

In other news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the stock in a transaction that occurred on Tuesday, September 19th. The stock was bought at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 28.40% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC purchased a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $104,000. Renaissance Technologies LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at about $132,000. Hikari Power Ltd boosted its holdings in Aldeyra Therapeutics by 186.4% during the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after acquiring an additional 70,196 shares during the period. Sabby Management LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at about $898,000. Finally, Vanguard Group Inc. boosted its holdings in Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares during the period. Institutional investors own 40.06% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply